Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

Posted on May 23, 2025 by MissionIR
  • The overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health.
  • Soligenix’s SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics.
  • Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection.

In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.

Antibiotics have been a cornerstone of modern medicine, effectively treating a wide range of bacterial infections. However, their overuse and misuse have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health. According to the Centers for Disease Control and Prevention (“CDC”), at least 2.8 million people in the United States are infected with antibiotic-resistant bacteria annually, resulting in more than 35,000 deaths (https://ibn.fm/qjibe).

The challenge is compounded by the fact that antibiotics are often specific to certain types of bacteria, and their efficacy can be compromised by resistance mechanisms. Moreover, the development of new antibiotics has not kept pace with the rapid evolution of resistant strains, leaving clinicians with limited options for treatment. Globally, the World Health Organization (“WHO”) has identified antimicrobial resistance as one of the top ten public health threats facing humanity. The situation is dire: if left unaddressed, it is projected that antibiotic resistance could cause 10 million deaths per year by 2050, surpassing cancer as a leading cause of death (https://ibn.fm/vC6MQ).

It is within this context that alternative approaches to bacterial infection treatment have become critically important. Soligenix’s SGX943 represents one such approach that could change the paradigm. SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics (https://ibn.fm/5RJFl). This promising therapy takes a fundamentally different approach by leveraging the body’s innate immune system rather than directly targeting pathogens, offering a powerful new tool in the fight against resistant bacterial infections.

Soligenix’s SGX943 therapy is based on dusquetide, an Innate Defense Regulator (“IDR”) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections.

One of the key advantages of SGX943 is its ability to be effective regardless of the bacterial species involved. This means it can be administered before the specific pathogen is identified, providing a timely intervention in acute infections. Additionally, SGX943 can be used in conjunction with existing antibiotics, potentially enhancing their efficacy and mitigating the development of resistance.

Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection, including those caused by antibiotic-resistant strains. Notably, the therapy has shown promise in treating melioidosis, a serious infection caused by Burkholderia pseudomallei, which is highly resistant to many antibiotics. The U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to SGX943 for the treatment of melioidosis, recognizing its potential to address an unmet medical need.

The rise of antibiotic-resistant bacteria underscores the critical need for innovative therapies that go beyond traditional antibiotics. Soligenix’s SGX943 offers a novel approach by harnessing the body’s innate immune system to fight infections, providing a versatile and potentially more effective treatment option. As the medical community continues to grapple with the challenges of antibiotic resistance, therapies like SGX943 represent a hopeful advancement in the fight against bacterial infections.

Headquartered in Princeton, New Jersey, Soligenix operates within the medical, biomedical and genetics sector. The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs. Among its leading candidates are HyBryte(TM) (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”), and SGX942 (dusquetide), designed to address oral mucositis in patients undergoing chemoradiation for head and neck cancer.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Posted on May 23, 2025 by MissionIR
  • Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics.
  • The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA.
  • Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer.
  • NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain.
  • HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical and technology-driven company, are expanding their footprint in the mental health care sector with the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California. The companies announced the signing of a definitive agreement to purchase the institute earlier in May 2025. Kadima is expected to serve as the clinical template for HOPE’s planned network of interventional psychiatry clinics across the U.S. (https://ibn.fm/uwHMj).

One of California’s flagship interventional psychiatry clinics, Kadima is recognized for integrating clinical care with research into emerging treatments such as psychedelic medications, and transcranial magnetic stimulation (“TMS”). The clinic offers a full range of treatments for suicidal depression, PTSD and other central nervous system (“CNS”) disorders. The institute was among the first in California to move ketamine treatments for mental health conditions out of academic research and into clinical settings.

According to the announcement, the acquisition will be accretive to revenue and EBITDA for both HOPE and NRx Pharmaceuticals. Kadima is currently profitable and expected to continue on a growth trajectory.

Dr. David Feifel, Kadima’s founder and medical director, will join HOPE as its first Chief Medical Innovation Officer after the acquisition closes. Dr. Feifel is widely regarded in the field of interventional psychiatry and has led numerous clinical trials targeting central nervous system disorders. His distinctions include serving as an elected member of the American College of Neuropharmacology, peer-elected inclusion in “Best Doctors in America,” and citation in the Castle Connolly list of “Top Doctors” — a recognition given to only 10 psychiatrists in San Diego. Dr. Feifel’s role at HOPE will be instrumental in shaping its clinical offerings and research integration.

The acquisition is still subject to customary closing conditions and financing. If completed, Kadima will become the first operational clinic under HOPE’s umbrella, setting the stage for additional acquisitions.

NRx Pharmaceuticals remains focused on the development of novel therapeutics for CNS conditions. The company’s lead compound, NRX-101, has been granted FDA Breakthrough Therapy Designation and is being developed for treatment-resistant bipolar depression with suicidality. The company is also pursuing development of NRX-100, a preservative-free IV ketamine formulation, for acute suicidality, which has received Fast Track status from the FDA.

The Kadima acquisition is part of HOPE’s broader plan to create a national network of interventional psychiatry clinics. The company aims to close on 30 such acquisitions by the end of 2025. HOPE projects $100 million in annual revenue and profitability by that time.

Commenting on the deal, Dr. Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE, said the signing of the definitive acquisition agreement marks a pivotal moment in the execution of the company’s strategy to redefine mental healthcare access and delivery of care. “Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team. With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care,” they said.

In addition to Kadima, HOPE has also announced agreements to acquire Dura Medical and signed a letter of intent with Neurospa TMS. These moves signal a push into outpatient psychiatric services at scale, a space seeing increased investor interest due to growing demand for mental health treatment options.

The strategy offers a dual approach to growth: a clinical-stage biotech company in NRx Pharmaceuticals, and a revenue-generating care delivery business in HOPE. The clinic network may also set the stage for a future spinout, offering NRx potential to unlock further shareholder value.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

FAVO Capital Inc. (FAVO): Positioned to Capitalize on Small Business Lending Revival

Posted on May 23, 2025 by MissionIR
  • FAVO Capital has filed to uplist to Nasdaq, aiming to scale its private credit model
  • U.S. small business lending is drawing renewed policy attention amid fintech innovation
  • FAVO strengthening strategic partnership with Stewards Investment Capital Limited through Series A equity Investment
  • Recently announced the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock

As traditional banks retreat from Main Street, alternative lenders are stepping up to fill the gap, reshaping the $1.7 trillion small business lending market in the process. With policymakers calling for renewed focus on small business financing and digital platforms redefining borrower access, private credit firms like FAVO Capital (OTC: FAVO) are emerging as essential players in the financial ecosystem. Backed by scalable technology, a seasoned leadership team, and a growing syndication network, FAVO is positioning itself for outsized growth at the intersection of policy tailwinds, market demand, and digital transformation.

Strategic Uplisting to Accelerate Growth

FAVO, a private credit firm focused on small and medium-sized businesses (“SMBs”), is laying the groundwork for its next growth phase. In February, the company filed a Form S-1 with the U.S. Securities and Exchange Commission, a move that signals its intent to uplist to the Nasdaq Capital Market.

The planned uplisting is more than a capital markets milestone, it’s a reflection of FAVO’s commitment to long-term growth, financial transparency, and operational scale. According to the company, the proceeds from its initial public offering will be used to reduce high-cost debt, invest in strategic initiatives, and expand technology-driven infrastructure. This financial optimization could position FAVO to enhance profitability while accelerating national expansion.

Recently, FAVO announced on May 13, 2025, the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock. This strategic move simplifies the company’s capital structure and aligns voting rights with public market expectations, reflecting FAVO Capital’s commitment to transparency and governance best practices. The conversion is a proactive step as the company continues preparations for its planned uplisting to Nasdaq.

“Converting our Series C Super Voting Shares demonstrates our commitment to transparency, governance and best practices as well as long-term value creation,” stated Vincent Napolitano, CEO of FAVO Capital. “It’s another important step forward as we align our structure with shareholder and institutional investor expectations.”

In addition to FAVO’s advancement towards Nasdaq, the company recently secured an $8 million Series A Preferred equity investment from strategic partner Stewards Investment Capital. This funding aims to accelerate direct SMB funding, restructure debt notes, and expand embedded lending partnerships, reinforcing FAVO to expand its operations. Stewards Investment Capital, already a significant shareholder following a $37 million acquisition deal in 2023, continues to support FAVO’s growth trajectory in the U.S. private credit market.

Filling a Growing Void in the Lending Ecosystem

FAVO’s timing may prove fortuitous. A renewed push from policymakers, potentially including President Trump, suggests the commercial banking industry could face pressure to return to its lending roots. Amid calls for banks to step up small business lending, non-bank lenders like FAVO are already playing an outsized role in meeting underserved financing demand.

Traditional banks have deprioritized small business loans in favor of global markets, trading operations, and wealth management services. As a result, a lending gap has formed in the U.S. market, where small businesses – those with fewer than 500 employees – make up nearly half of all economic activity. FAVO Capital is part of a new wave of alternative lenders stepping in to bridge this divide.

With more than $140 million funded to over 10,000 businesses since inception, FAVO brings real scale and momentum to this market. If regulatory or political changes make traditional lenders even slower to respond, private credit firms with flexible underwriting and tech-enabled operations could see demand surge.

Tech-Driven Efficiency Meets Real-World Impact

At the heart of FAVO’s competitive advantage is its technology-focused lending model. The company continues to build and refine its proprietary CRM platform, which enables efficient underwriting, customer service, and deal syndication. In a digital-first lending landscape, that infrastructure is essential, not just for cost efficiency, but for maintaining relationships with borrowers in real time.

According to industry insights, digital lending platforms have become central to the evolution of the private credit market. Their ability to process data, personalize loan structures, and streamline approvals gives them a clear edge over legacy systems. FAVO is investing in these capabilities while maintaining its human-centric service approach, combining fintech innovation with the high-touch needs of SMB borrowers.

This hybrid model, combined with the firm’s existing footprint and syndication track record, puts it in a strong position to scale as economic conditions stabilize and capital becomes more accessible.

A Compelling Play on Lending Resurgence

FAVO’s leadership team sees the uplisting as a key inflection point. By enhancing liquidity, improving investor access, and optimizing its cost of capital, the company is positioning itself for long-term relevance in an evolving private credit environment.

As big banks face political pressure to revisit their role in small business lending—and as digital lenders continue to grow in popularity—FAVO’s model stands at the crossroads of policy, technology, and capital market readiness. Investors looking for exposure to the future of private credit may find FAVO to be an early-stage player with meaningful traction and significant upside.

For more information, visit the company’s website at FavoCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in FAVO Capital Inc. FAVO | Leave a comment

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Posted on May 23, 2025 by MissionIR
  • Intelligent Bio Solutions remains on track for a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System.
  • The company’s FDA 510(k) submission included validation studies showing 94.1% accuracy in detecting opiates through fingerprint sweat.
  • INBS is already active in 24 countries, with over 450 commercial accounts globally, and adoption growing across diverse industries, including logistics, mining, retail, and marine operations.
  • The firm is expanding its distributor network to support localized growth ahead of its U.S. market entry.

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S. launch in 2025, as it is progressing through the FDA clearance process for its Intelligent Fingerprinting Drug Screening System. The non-invasive device, which detects recent drug use via fingerprint sweat, is gaining international traction for its speed, portability, and ability to integrate into a range of safety-critical environments.

On Dec. 18, 2024, INBS submitted a 510(k) premarket notification to the U.S. Food and Drug Administration, seeking clearance for its opiate test system for codeine (https://ibn.fm/YVRNE). The FDA classified the system as a Class II medical device, which requires this form of submission. As of March 2025, the FDA has issued an Additional Information (“AI”) request, a standard part of the review process that pauses the 90-day review clock while the company prepares its response.

The 510(k) filing includes data from method comparison and pharmacokinetic studies. INBS reported a 94.1% accuracy rate in its performance evaluations and emphasized that fingerprint sweat provides a viable and statistically consistent alternative to blood for drug detection. According to the company, these findings support its plans to launch the platform in the U.S. and expand the system’s testing panel to additional drug classes over time.

“We appreciate the thoroughness of the FDA’s process, which aligns with our expectations. As we await FDA clearance, we remain confident in the strength of our data, which demonstrates the accuracy, reliability, and usability of our technology,” said Harry Simeonidis, President and CEO of INBS. “We are actively preparing for our planned U.S. launch in 2025, where we see significant opportunities to revolutionize drug screening with our non-invasive, rapid testing solution.”

Outside the U.S., INBS continues to expand its commercial footprint, reflecting rising global demand for drug screening technologies that can deliver fast, reliable results without the logistical challenges of traditional methods. As of May 2025, the company reported more than 450 active accounts across 24 countries, with 35 new clients added in the third fiscal quarter alone (https://ibn.fm/CgnKV).

Growth is being driven by industries where on-site, rapid testing is critical. INBS has seen adoption in sectors including transportation, engineering, logistics, mining, and, most recently, luxury marine operations in Europe. In Australia, the technology has gained traction in remote testing programs, waste management, and retail, including implementation by a major e-commerce brand.

To support expansion, INBS is building out its distributor network, which now spans 19 countries through 18 regional partners. The company is also preparing to offer collected testing services, aimed at organizations that require centralized testing capacity for high volumes.

The fingerprint-based screening system delivers results in under ten minutes and does not require specialist medical personnel to administer. This ease of use, combined with its compact form factor and accuracy, makes it attractive to organizations managing distributed or mobile workforces.

Doug Heath, INBS’s Vice President of Global Sales, said the technology is resonating with clients seeking a simpler and faster alternative to traditional urine or saliva tests. “Traditional testing methods aren’t keeping up with operational demands – our solution is,” Heath said. “Industries are moving quickly to adopt a system that’s fast, diverse in its capabilities, and easy to implement.”

For more information, visit the company’s website at https://ibs.inc.

NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Intelligent Bio Solutions Inc. INBS | Leave a comment

MissionIRNewsBreaks – Soligenix Inc.’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer Trial

Posted on May 22, 2025 by MissionIR

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is leading the way with innovative therapies for rare and difficult-to-treat diseases, particularly early-stage cutaneous T-cell lymphoma (“CTCL”), a rare form of cancer that affects the skin. “Soligenix’s proprietary treatment, HyBryte(TM), is currently in clinical trials, and the latest results have shown promising efficacy in treating CTCL,” reads a recent article. “‘Following 18 weeks of treatment, 75% of patients achieved ‘Treatment Success,’ reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer,’ the company reported. The study results suggest that the treatment may be highly effective in reducing the symptoms of CTCL, providing much-needed hope for patients with this challenging condition.”

To view the full article, visit https://ibn.fm/I24jb

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

MissionIRNewsBreaks – Precision Meets Performance: Newton Golf Company Inc.’s (NASDAQ: NWTG) Fitted Shafts Elevate the Game

Posted on May 22, 2025 by MissionIR

Newton Golf Company (NASDAQ: NWTG) is revolutionizing golf performance through its high-quality, custom-fitted shafts engineered to match individual swing dynamics. Recognizing the shaft as the “engine” of the club, Newton leverages advanced technology to optimize swing speed, ball trajectory and overall control. Crafted in the U.S. and engineered to meet the demands of players on professional tours, 30 PGA TOUR Champions players trust the shaft—including major winner Doug Barron. From seasoned pros to players across all skill levels, the company delivers precision equipment that minimizes inconsistencies and enhances shot accuracy for all golf enthusiasts. As personalized equipment gains traction in the golf industry, Newton Golf is emerging as a leader, helping players unlock their true potential on the course.

To view the full article, visit https://ibn.fm/Ankz9

About Newton Golf Company Inc.

Newton Golf harnesses the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, the company’s rebranding reflects its commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of its design process, Newton Golf creates precision-engineered golf clubs that deliver unmatched stability, control, and performance. The company’s mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

For more information, visit the company’s website at www.NewtonGolfIR.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in Newton Golf Comp. NWTG | Leave a comment

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

Posted on May 22, 2025 by MissionIR
  • AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report
  • Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment
  • Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization

In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including a strong partnership with Kindeva Drug Delivery.

“Nutriband is primarily focused on working with our partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop our lead product, AVERSA(TM) Fentanyl, which incorporates Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch,” stated Sheridan in the letter.

“AVERSA Fentanyl has the potential to become the world’s first opioid pain patch with abuse deterrent properties and is estimated to potentially reach peak annual sales of $80 million–$200 million,” he continued. “In addition, AVERSA Buprenorphine, our next candidate for AVERSA, is projected to reach peak annual sales of $70 million–$130 million. Nutriband recently performed an extensive evaluation of the commercial cost of goods of incorporating the AVERSA technology into existing FDA-approved transdermal patches and has confirmed the viability of achieving high margins that are typically found in NDA pharmaceutical products.”

Sheridan noted that Nutriband and Kindeva have formalized an exclusive product-development partnership and long-term commitment based on shared development costs in exchange for milestone payments. This agreement “solidifies a transition to commercial scale development for AVERSA(TM) Fentanyl,” he noted.

“We have confidently shifted our focus from feasibility towards commercial development in support of an NDA filing and commercialization,” Sheridan observed. “This was a very strong show of support from our partner Kindeva, which also allowed us to reduce the impact of dilution to our existing shareholders, which I stress has been and will remain a core focus of the company. This was evident through our raise of $8.4 million in April 2024 in a nonbrokered private placement primarily through existing shareholders.”

In addition to the company’s partnership with Kindeva, Sheridan noted other key steps taken as Nutriband works to develop and scale-up the manufacturing process to bring Aversa technology closer toward commercialization. Those steps have included developing and refining Nutriband’s proprietary technology for commercial scale manufacturability, establishing the commercial supply chain and validating the analytical methods required to meet U.S. Food and Drug Administration (“FDA”) regulatory standards for a pharmaceutical product.

Nutriband has also expanded the worldwide intellectual property portfolio for its AVERSA abuse deterrent technology, the shareholder report noted. That expansion has included approvals in China and its territories, Hong Kong and Macao, as well as a new patent approval in the United States.

“This improves our position to bring our leading abuse deterrent platform to market,” Sheridan explained. “We are now patented in 46 countries around the world. While initially concentrating on the U.S. market, the unmet medical need for adequate pain management is a global problem, and our goal is to make a global solution strategically targeting all major medical markets in the world.”

In the report, Sheridan outlined the company’s “ambitious yet achievable” 2025 goals. Nutriband will work on getting into the clinic to evaluate its lead product, AVERSA(TM) Fentanyl, in a pivotal Human Abuse Liability (“HAL”) clinical trial, which be key for an NDA filing. This will involve manufacturing clinical supplies using a commercial scale process as well as filing an Investigational New Drug application with the FDA. The company is also exploring new potential international partnerships for its AVERSA intellectual property and will be evaluating licensing and partnership opportunities, all while working to have the AVERSA(TM) Fentanyl product to be used in mass soon.

Sheridan also pointed out the strong revenue numbers reported by Nutriband’s Pocono Pharma subsidiary for its kinesiology tape contract manufacturing services. Company officials believe that 2025 is shaping up to be Pocono Pharma’s best year on record due to its expanding manufacturing collaboration with KT Tape, the world leader in kinesiology tape.

“Many of you have been with us from the beginning,” Sheridan concluded. “And many more joined our mission to change the pharmaceutical industry for the better by developing our AVERSA technology designed to improve the safety of easily abused transdermal drugs, such as pain medications, while making them available to patients who need them. Pain patients have been struggling with inadequate care for too long, and they deserve to be able to access the medication they need. AVERSA gives them this access. Today we are on track to be the world’s first and only abuse deterrent technology in the transdermal space targeting abusable medications such as fentanyl and buprenorphine.”

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

FAVO Capital Inc. (FAVO): Filling the Financing Gap for Underserved SMBs

Posted on May 22, 2025 by MissionIR
  • FAVO Capital is developing a digital lending platform tailored to small and medium-sized businesses, targeting gaps left by traditional banks
  • Proprietary fintech tools and flexible financing solutions aim to provide capital access for businesses that are often denied by legacy lenders
  • Rising demand for alternative credit sources presents a major opportunity for agile, tech-driven lenders like FAVO

With over 5.5 million new business applications filed in the U.S. last year alone, small- to medium-sized businesses (“SMBs”) are thriving, but many are finding themselves underserved by traditional financial institutions. According to recent industry insights, 6 in 10 SMBs are denied access to essential funding due to outdated underwriting processes that fail to reflect their real financial health.

This growing disconnect has paved the way for fintech innovators to step in with more inclusive, tech-enabled lending models. Among these players is FAVO Capital (OTC: FAVO), a company focused on delivering fast, flexible, and accessible capital solutions for SMBs that are often overlooked by banks.

Proprietary Technology to Modernize SMB Financing

FAVO Capital is currently developing a proprietary lending platform and mobile app designed to streamline the funding process for business owners. Once launched, this digital ecosystem will allow clients to apply for funding, track their progress, and manage repayments through a user-friendly interface.

In parallel, the company is exploring the integration of advanced analytics and alternative data sources into its credit decision-making. By evaluating factors like cash flow, vendor payment behavior, and transaction histories, FAVO aims to provide more predictive, fairer assessments of creditworthiness, especially for businesses that may not have an established credit file.

Flexible Products for Real-World Business Needs

FAVO Capital doesn’t rely on one-size-fits-all products. Instead, it structures customized capital solutions that evolve alongside its clients’ needs. Whether it’s short-term working capital or a longer-term growth initiative, the company’s financing products are designed to be adaptive, helping business owners overcome real-world financial hurdles.

This kind of lending agility is especially valuable for low-revenue or newly formed SMBs, many of which require loans of $100,000 or less, an amount most traditional banks don’t prioritize.

A Market Ready for Disruption

With SMBs representing 99.9% of all American businesses and contributing roughly 40% of U.S. GDP, the need for modern funding solutions is not only massive but urgent. As traditional credit models struggle to meet the diverse and fast-moving demands of small businesses, companies like FAVO Capital are positioned to gain traction.

By leveraging fintech tools, proprietary platforms, and a customer-first approach, FAVO Capital could play a vital role in transforming how American small businesses access the capital they need to grow, compete, and thrive.

For more information, visit the company’s website at FAVOCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in FAVO Capital Inc. FAVO | Leave a comment

MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

Posted on May 21, 2025 by MissionIR

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital.

The presentation will highlight the company’s progress toward FDA approval of NRX-100, a preservative-free intravenous ketamine formulation, as well as its strategic acquisition plans for HOPE clinics focused on treating suicidal depression, PTSD, and related conditions.

To view the full press release, visit https://ibn.fm/YPsOc

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRx has recently initiated a New Drug Application filing for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

For more information, please visit https://www.nrxpharma.com/

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

FAVO Capital Inc. (FAVO) Delivering Funding Solutions in Private Credit Market, Poised for Significant Growth

Posted on May 20, 2025 by MissionIR
  • Momentum suggests a positive trajectory in the private credit market in the coming year.
  • FAVO Capital offers flexible capital solutions tailored to SMBs’ unique needs.
  • The company’s approach exemplifies how private credit firms are leveraging technology to enhance their offerings.

The private credit market is on the cusp of substantial expansion in 2025, driven by a resurgence in global mergers and acquisitions (“M&A”), the digitization of lending processes and the emergence of innovative financing solutions tailored for small and medium-sized businesses (“SMBs”) (https://ibn.fm/pDNA4). This confluence of factors is reshaping the financial landscape, as companies such as FAVO Capital (OTC: FAVO) are strengthening their foothold in the growing space.

“Global M&A is recovering from its 10-year low, as global GDP outperformed expectations and central banks began easing monetary policy,” reported global financial services group Macquarie in a recent report. “Though activity levels remain well below the long-term average, last year deal volumes grew 7%, according to data from Preqin, and values increased 15% to $3.5 trillion, edging the market closer to pre-pandemic levels.” This uptick reflects growing confidence among dealmakers, fueled by improving economic conditions and pent-up demand, the report continued, with Bill Eckmann, head of Principal Finance and Private Credit at Macquarie Capital, emphasizing that while deal flow remains below normalized levels, the momentum suggests a positive trajectory for the coming year.

Parallel to the M&A resurgence, the digitization of lending is significantly transforming small business financing. By integrating new technologies and data into operations, digitization streamlines processes, making lending more accessible and efficient for both lenders and borrowers. This technological shift enhances the speed and accuracy of credit assessments, enabling lenders to better evaluate the creditworthiness of small businesses. Consequently, entrepreneurs benefit from expedited loan approvals and more tailored financing solutions.

However, the adoption of digital lending technologies is not without challenges, according to a recent article from the Bipartisan Policy Center (https://ibn.fm/dzHzF). Concerns regarding data privacy, security risks and the potential for algorithmic biases necessitate careful consideration and regulation. Ensuring that these digital tools are implemented responsibly is crucial to maintain trust and fairness in the lending process.

Amid these industry shifts, private credit firms are stepping up to bridge the financing gap for SMBs. FAVO Capital, for instance, is a rapidly growing private credit company dedicated to providing fast, efficient, and personalized funding solutions for small and medium-sized businesses. Recognizing the challenges businesses face in securing traditional financing, FAVO Capital offers flexible capital solutions tailored to their unique needs.

FAVO Capital has more than $138 million in total funding supporting more than 10,000 businesses. The company leverages artificial intelligence (“AI”)-powered analytics to provide faster, smarter funding decisions. Publicly listed and regulated, FAVO Capital is committed to transparency and investor confidence. The company has expanded its market reach, currently operating in 45 states and the Dominican Republic. FAVO’s fast, flexible financing can result in funding delivered within hours, as it executes on its strategic expertise combined with cutting-edge fintech solutions.

FAVO Capital’s approach exemplifies how private credit firms are leveraging technology to enhance their offerings. By utilizing technology-driven underwriting and alternative financing solutions, the company empowers businesses with the capital they need without the restrictions of traditional lenders. This strategy not only accelerates the funding process but also provides more customized financing options that align with the specific requirements of SMBs.

For more information, visit the company’s website at FAVOCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
[email protected]

MissionIR is powered by IBN

Posted in FAVO Capital Inc. FAVO | Leave a comment